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MeningesAbstract Introduction: Fibrosarcoma is a rare brain tumour with 33 cases reported so far.
However, there is no clear consensus about the nature of the disease and treatment as well as out-
come.
Methods: A MEDLINE search was carried out using MESH terms like intracranial ﬁbrosarcoma,
intraspinal ﬁbrosarcoma, ﬁbrosarcoma meninges and ﬁbrosarcoma brain. A total of 22 case reports
and series reporting a total of 33 cases were identiﬁed. We here also report a case treated in our
institute with adjuvant radiation and concurrent and maintenance temozolomide.
Results: The age of presentation ranged from 2 months to 75 years (Median = 17 years). The gen-
der ratio was found to be M:F of 1.75–1. Treatment modalities were described for 17 cases. Surgery
was part of treatment in all cases while radiation was a part of treatment in 59% of cases (n= 10)
and chemotherapy in 29% cases (n= 5). Survival data were available only for 8 cases and ranged
from 1 day to 8 years (Median = 15.5 months).
Conclusion: Fibrosarcoma is a rare disease with dismal prognosis. Surgery remains the cornerstone
of therapy. Radiation confers long term disease control and survival. Chemotherapy needs to be
evaluated for these tumours to improve survival.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Fibrosarcoma of the brain is a rare tumour with a poor prog-
nosis. These tumours have been hypothesized to arise from
ﬁbroblastic cells of meninges. It has been reported to be asso-
ciated with radiation and chemotherapy exposure. These
tumours share common radiologic feature to that of menin-
gioma. Surgery has long been considered the treatment of
Table 1 Dose constraint used in the present case.
Organ at risk Dose constraints Dose
achieved
Brainstem Dmax < 54 Gray 50.48 Gray
Opposite temporal lobe Dmax < 60 Gray 43.60 Gray
Optic chiasma Dmax < 54 Gray 20.94 Gray
Right optic nerve Dmax < 54 Gray 7.51 Gray
Left optic nerve Dmax < 54 Gray 5.74 Gray
Right eye Dmean < 35 Gray 2.26 Gray
Left eye Dmean < 35 Gray 3.19 Gray
Right eye lens Dmax < 10 Gray 2.19 Gray
Left eye lens Dmax < 10 Gray 1.31 Gray
Right lacrimal gland Dmean < 20 Gray 2.19 Gray
Left lacrimal gland Dmean < 20 Gray 1.29 Gray
Hippocampus Dmean < 7.3
Gray
39.62 Gray
Hippocampal avoidance
zone
Dmean < 7.3
Gray
38.21 Gray
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failure and paved for the use of radiation to improve survival.
Because of the propensity of systemic failure chemotherapy
also appears an important component of the treatment. We
herein present a case of intracranial ﬁbrosarcoma treated in
our institute and review all published cases to arrive at some
conclusion regarding the behaviour and treatment outcome
of ﬁbrosarcoma.
Search methodology
A MEDLINE search was carried out using MESH terms like
intracranial ﬁbrosarcoma, intraspinal ﬁbrosarcoma, ﬁbrosar-
coma meninges and ﬁbrosarcoma brain. A total of 22 case
reports and series reporting a total of 33 cases were identiﬁed.
However, detailed information was not available in many
reports.
Inclusion and exclusion criteria
Cases of intracranial ﬁbrosarcoma of any age were included.
Fibrosarcoma of any other location with metastasis to brain
was excluded from the present analysis.
Data entry and analysis
The available data were tabulated for age, sex, presenting
symptoms, location of tumour, imaging ﬁndings, associations,
histopathology and immunohistochemistry, treatment modali-
ties used and survival. The median age of presentation and
median survival were calculated.
Case report
A 66 year old male presented with a 2 month history of head-
ache, weakness on the left side of the body and deviation of
angle of mouth towards the right side. The patient had a his-
tory of pulmonary tuberculosis 20 years back treated success-
fully with anti-tubercular therapy. A contrast enhanced MRI
of the brain revealed a homogenous well circumscribed large
mass in the right posterior frontal and parietal region showing
uniform intense contrast enhancement with clear line of cleav-
age between it and the brain parenchyma suggestive of menin-
gioma (Fig. 1). The patient underwent right fronto-parietal
craniotomy with gross total excision of the space occupying
lesion. The post-operative histopathology was reported to be
ﬁbrosarcoma positive for vimentin on immunohistochemistry.
A PET-CT was done to rule out metastases or extracranial pri-
mary. The PET-CT revealed no abnormal FDG uptake.
Subsequently, the patient was planned for post-operative
radiotherapy of 60 Gray 30 fractions over 6 weeks with con-
current temozolomide (75 mg/m2) followed by maintenance
temozolomide for 6 months (150–200 mg/m2 D1–D5 repeated
every 4 weeks). Radiation was planned on pinnacle version
8.0 with 3 D conformal radiation therapy. The CTV50
included the T2 ﬂair abnormality with 2.5 cm isotropic expan-
sion. The CTV60 was taken as disease evident in the T1
weighted image with 1.5 cm isotropic expansion. PTV was cre-
ated with a 3 mm isotropic margin for both the CTV. The
patient was treated on the Synergy S with kV-CBCT imageguidance. The dose constraints given and achieved are tabu-
lated in Table 1. The patient tolerated the treatment well with-
out any interruptions. The patient is asymptomatic and disease
free at 6 months post diagnosis.
Literature review
The age of presentation ranged from 2 months to 75 years
(Median = 17 years). The gender ratio was found to be M:F
of 1.75–1. Headache was the most common symptom followed
by generalized tonic clonic seizures and scalp swelling. Four
cases have been reported to be associated with previous radia-
tion exposure whereas one case was associated with exposure
to multi-agent chemotherapy. Enhancing mass was seen on
imaging in all cases while haemorrhage and bone destruction
were described in two cases. Treatment modalities were
described for 17 cases. Surgery was part of treatment in all
cases while radiation was a part of treatment in 59% of cases
(n= 10) and chemotherapy in 29% cases (n= 5). Both
chemotherapy and radiation were used in 23% of cases
(n= 4). Survival data were available only for 8 cases and ran-
ged from 1 day to 8 years (Median = 15.5 months). Out of 17
cases for which data were available, 11 patients had a local
recurrence and six patients experienced systemic recurrence.
The details of patient characteristics, treatment and outcome
have been summarized in Table 2.
Discussion
Intracranial ﬁbrosarcoma is a rare entity with 33 cases
reported in the available literature. They have been described
as arising de novo or arising as secondary tumours in patients
who have received radiation therapy to the brain [1–5] and in
patients who have been treated with chemotherapy for
glioblastoma [6]. They have been described in patients with a
history of meningioma [7] and also in association with menin-
gioangiomatosis [8].
They have been described in ages ranging from 2 months to
75 years of age. Most cases described are intracranial. Only
Figure 1 Axial, coronal, sagittal section of a contrast enhanced MRI of brain revealed a homogenous well circumscribed large mass in
right posterior frontal and parietal region showing uniform intense contrast enhancement with clear line of cleavage between it and the
brain parenchyma suggestive of meningioma.
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literature search.
On imaging, the location of tumour is more commonly
superﬁcial than deep. It is usually seen as a hypointense well
circumscribed superﬁcial mass with or without a dural tail
on T1 images without contrast and as a homogenously inten-
sely enhancing mass on T1 images with Gadolinium contrast.
Minimal peri-lesional oedema is seen. Haemorrhage within the
tumour is rare but has been described in the literature [9,10].
Overlying bone destruction has also been described in a few
cases [11,12]. The most common differential on imaging is
meningioma. The two can be differentiated by the absence of
dural tail in ﬁbrosarcoma, a more aggressive clinical course
and by histology.
The origin of ﬁbrosarcoma is believed to be the ﬁbrob-
lastic elements of the meninges. On histology, a characteris-
tic Herring bone pattern alternating with collagenous matrix
is seen. Absence of whorling and Psammoma bodies helps
to differentiate ﬁbrosarcoma from meningioma. On IHC,
ﬁbrosarcoma is Vimentin positive and sometimes cytoker-
atin and GFAP positive. They are CD 34 and CD 99
negative.
The most common symptom described is headache of short
duration. Other common symptoms are generalized tonic clo-
nic seizures and slow growing scalp swelling without neurolog-
ical deﬁcit. Rarely, these tumours present with symptoms like
episodic word ﬁnding difﬁculty and paraparesis.
There is no consensus regarding the optimum treatment
of ﬁbrosarcoma of the brain. Maximal safe resection of
tumour should be the initial treatment. Post-operative radia-
tion should be initiated as early as possible as early recur-
rences in the post-operative bed have been described inpatients in whom chemotherapy was initiated as an adjuvant
treatment [4,13]. Varied dose fractionations of radiation
have been used. Radiation has been delivered by external
beam, gamma knife and also gliasite brachytherapy [10,14].
A dose of 55–60 Gray in conventional fractionation has pro-
vided a durable response in few case reports [13–15]. We
recommend the use of 60 Gray in 30 fractions over 6 weeks
as adjuvant radiation 4–6 weeks after surgery. The target
volumes to be used are also not well deﬁned but in view
of aggressive nature of the disease and its tendency to recur
in the operative bed, the target volumes used for high grade
glioma appear justiﬁed.
Despite the use of surgery and post-operative radiotherapy,
the prognosis of this tumour has been poor. These tumors have
potential for local as well as distant metastasis, with local fail-
ure being the commonest [16]. In a study by Gaspar et al., the
median survival was 7.5 months and more than 55% patients
recurred within 6 months [16]. Our review deﬁnes a median
survival of 15.5 months. Thus newer treatment protocols need
to be formulated and integrated with the present treatment.
Long term remissions have been described with the use of high
dose chemotherapy and bone marrow transplant [6]. In a study
by Gonzalez-Gomez et al. on neuroﬁbromas and neuroﬁ-
brosarcomas, aberrant methylation of MGMT methylation
was found in 43% cases [17]. In a case report of ovarian
ﬁbrosarcoma which like intracranial ﬁbrosarcoma carry a poor
prognosis, long term remission of 6 years was achieved by the
use of surgery and adjuvant chemotherapy with epirubicin,
ifosfamide and dacarbazine [18]. The penetration of epirubicin
intracranially is poor. In view of high percentage of MGMT
methylation in these tumours, it appears logical to add temo-
zolomide with radiation as an adjuvant treatment.
Table 2 Summarizes all published cases.
Authors n Age Sex Symptoms Association Location Imaging IHC Rx Survival
Smith et al.
(1969) [19]
1 – – – Synchronous GBM and
Fibrosarcoma
Intracranial – – – –
Schrantz
and Araoz
(1972) [2]
1 – – – Radiation induced Intracranial – – – –
Shujman
et al. (1976)
[20]
1 – – – None Intracranial – – – –
Reynier
et al. (1984)
[21]
4 – – – None Intracranial – Haemorrhagic
zones, osteoid
metaplasia,
GFAP+
Surgery f/b radiotherapy –
Mizuno
et al. (1989)
[3]
1 16 M Lt eye lid swelling History of B/L RB-
treated by enucleation
and radiotherapy at one
year of age.
LT frontal
lobe
– Vimentin+ Surgical debulking f/b
chemoradiation of cisplatin and
etoposide and WBRT to 26 Gy
CR achieved in
3 months. OS
not mentioned.
Yamamoto
et al. (1989)
[4]
1 19 F Multiple episodes
of intracranial
bleeding
H/O of
craniopharyngioma
treated with radiotherapy
10 years back.
Vimentin+ Multiple surgeries f/b chemo
with carmustine, cisplatin and
adriamycin
Progressive
disease
Rovirosa
et al. (1992)
[11]
1 – – Scalp swelling –
slow growing. No
neurology deﬁcit
None Parietal lobe Bone destruction – Surgery –
Gaspar
et al. (1993)
[16]
9 22–61 – – None Intracranial 5
– superﬁcial 4
– deep
– Vimentin – 5
Cytokeratin-2
GFAP-2
Surgery f/b radiotherapy 45–60
Gray
Median survival
7.5 months. 5
patients
recurred within
6 months
Aydin et al.
(1995) [5]
1 9.5 M Headache H/O medulloblastoma.
Treated by CSI
15 months back.
Cerebral
convexity
Vimentin+ Not mentioned Not mentioned.
McDonald
et al. (1997)
[9]
1 43 F – None Intracranial Spontaneous
haemorrhage into
sarcoma – ﬁrst
case reported
– Surgery –
Donnet
et al. (1999)
[7]
1 – – Sudden loss of
consciousness and
coma
H/O meningioma for
10 years on follow up
Frontal lobe En plague
Meningioma,
enhancing frontal
lesion
– Surgery Not mentioned
Vatsal et al.
(2000) [22]
1 38 M GTCS for 20 years.
Intracranial space
occupying lesion
found after
20 years. Headache
for 3 months
Left parieto-
occipital site
Vimentin+ Surgery f/b radiotherapy Not mentioned
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Kaminski
et al. (2000)
[6]
1 5 F GTCS H/o GBM in infancy.
Treated by gross total
resection f/b CCG-921
protocol 8 in 1
chemotherapy. Complete
response for 5 years.
Left
frontoparietal
site
Vimentin+ Surgery GTE done for
ﬁbrosarcoma. Recurred in
3 months. Again GTE done. RT
59.6 Gray/ 33 # done. High dose
chemotherapy f/b bone marrow
transplant done
NED at 8 years
Robert
Fraser et al.
(2001) [14]
1 34 F Left sided weakness Recurred in 1 month Right fronto
parietal
junction
– Vimentin+ Surgery f/b recurrence in
1 month f/b resurgery f/b gliasite
brachytherapy 152 Gray at
surface f/b EBRT 46 Gray/23 #
f/b ifosfamide
NED at
18 months
Bisogno
et al. (2002)
[13]
1 13 M Headache, right
arm paraesthesia
and vomiting
Left temporo-
parietal site
– Vimentin+ Surgery f/b chemotherapy with
VAIA. Recurrence in two
months. RT given 57.6 Gray/ 32
#/ 6.5 weeks
NED at
44 months
Cai and
Kahn
(2004) [8]
1 9 – Headache and
vomiting
Associated
meningioangiomatosis.
Intracranial – – Surgery –
Adleye
et al. (2009)
[23]
1 43 M Headache and
dysphasia
None Left frontal
lobe
Non-
homogenously
enhancing mass
with peri-lesional
oedema
GFAP –
Vimentin+
Surgery f/b RT 54 Gray/30 #/
6 weeks f/b TMZ for two cycles.
Recurrence after
three months.
GTE done f/b
Cyber knife 17
Gray.
Chopra
et al. (2010)
[15]
1 13 M GTCS f/b headache Frontal trauma one
month back
Left frontal Enhancing mass
on MRI
Vimentin+ Surgery f/b RT Disease free at
33 months
Brohi and
Dilber
(2012) [12]
1 2 months – Scalp swelling –
slow growing. No
neurology deﬁcit
Congenital Intracranial Osteolytic
enhancing lesion
compressing
atrophic brain
– Surgery and duroplasty –
Kunert
et al. (2012)
[1]
1 – – – Radiation Induced Intracranial – – Surgery –
Lee et al.
(2013) [10]
1 17 M Headache followed
by seizures
B/L frontal Haemorrhagic
mass on CT. MRI
enhancement. B/L
ACA major
feeding vessel on
arteriography
Vimentin+ Surgery f/b gamma knife – 18
Gray to 55 % isodose
Not mentioned
Present case 1 66 M Headache, limb
weakness
None Right
posterior
fronto-parietal
Uniform intense
contrast enhanced
mass
Vimentin+ Surgery f/b adjuvant RT 60
Gray/30 #/6 weeks with
concurrent and maintenance
TMZ
NED 4 months
GBM – glioblastoma; GFAP – glial ﬁbrillary acidic protein; RB – retinoblastoma; WBRT – whole brain radiotherapy; CSI – craniospinal irradiation; GTCS – generalized tonic clonic seizures; GTE
– gross total excision; RT – radiotherapy; EBRT – external beam radiotherapy; VAIA – vincristine, actinomycin D, ifosfamide, adriamycin; ACA – anterior cerebral artery; TMZ – temozolomide.
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Fibrosarcomas of the brain are rare tumours with a poor prog-
nosis. Addition of adjuvant radiation after maximal safe resec-
tion has the potential to improve long term disease control and
survival. In view of chances of distant recurrence, systemic
chemotherapy merits evaluation.
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